Compare FWRD & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FWRD | VIR |
|---|---|---|
| Founded | 1981 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 512.4M | 1.5B |
| IPO Year | 2024 | 2019 |
| Metric | FWRD | VIR |
|---|---|---|
| Price | $16.71 | $8.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $38.50 | $19.63 |
| AVG Volume (30 Days) | 755.0K | ★ 2.8M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 88.54 | 17.49 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,269,573,000.00 | $68,556,000.00 |
| Revenue This Year | $6.57 | N/A |
| Revenue Next Year | $6.66 | $1,049.62 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.79 | $4.16 |
| 52 Week High | $32.47 | $10.91 |
| Indicator | FWRD | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 35.41 | 50.96 |
| Support Level | $15.28 | $8.67 |
| Resistance Level | $30.48 | $10.29 |
| Average True Range (ATR) | 0.95 | 0.46 |
| MACD | 0.25 | -0.15 |
| Stochastic Oscillator | 58.20 | 40.57 |
Forward Air Corp is an asset-light freight and logistics company. The company's operating segment includes Expedited Freight, Omni Logistics, and Intermodal and Corporate. The company generates maximum revenue from the Omni Logistics segment. The expedited Freight segment operates a comprehensive national network to provide expedited regional, inter-regional, and national LTL (less-than-truckload) services. It also offers customers local pick-up and delivery and other services including final mile, truckload, shipment consolidation and deconsolidation, warehousing, customs brokerage, and other handling. The Company conducts business in North and South America, Europe, and Asia.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.